Influenza virus vaccine
Highest phase reached
Phase 3
Drug type
Vaccine component
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Vaccine component
- Drug name
- Influenza virus vaccine
- fluzone quadrivalent influenza virus vaccine
- influenza live attenuated
- influenza virus vaccine
- Influenza virus vaccine
- Influenza Virus Vaccine
- Influenza virus vaccine (2004-2005 Formulation)
- Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)
- Influenza virus vaccine (2007-2008 Formulation)
- Influenza virus vaccine (CAIV-T)
- Influenza virus vaccine (Fluviral)
- influenza virus vaccine (influvac or vaxigrip)
- Influenza virus vaccine (Pediatric formulation)
- Influenza Virus Vaccine(contains Preservative)
- Influenza Virus Vaccine(no Preservative )
- Influenza, live attenuated
- ATC classification codes
- J07BB03
Sources for recorded values
- ChEMBL ID
- CHEMBL2109042
- Patents
- 0
- Designations
- 0
- Earliest recorded loss of exclusivity
- 16 Jan 2025
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- vir-
- Condition
- Gonorrhea
- Highest recorded phase
- 2
- Condition identifier
- DOID:7551
- Subject identifier
- D006069
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Astrocytoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000272
- Subject identifier
- D001254
- Condition
- Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Oligodendroglioma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000632
- Subject identifier
- D009837
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- HIV Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Pneumococcal Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000772
- Subject identifier
- D011008
- Condition
- Arthritis, Juvenile
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0002609
- Subject identifier
- D001171
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Multiple Sclerosis, Relapsing-Remitting
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003929
- Subject identifier
- D020529
- Condition
- Influenza in Birds
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005222
- Subject identifier
- D005585
- Condition
- Orthomyxoviridae Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005226
- Subject identifier
- D009976
- Condition
- Acute Coronary Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005672
- Subject identifier
- D054058
- Condition
- Herpes Zoster
- Highest recorded phase
- 3
- Condition identifier
- EFO:0006510
- Subject identifier
- D006562
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0006859
- Subject identifier
- D006258
- Condition
- Influenza, Human
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
- Condition
- Orthomyxoviridae Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007411
- Subject identifier
- D009976
- Condition
- Aging
- Highest recorded phase
- 2
- Condition identifier
- EFO:0022597
- Subject identifier
- D000375
- Condition
- Central Nervous System Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000158
- Subject identifier
- D016543
- Condition
- Paraganglioma
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000453
- Subject identifier
- D010235
- Condition
- Escherichia coli Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001318
- Subject identifier
- D004927
And 8 more, listed on the interactive page.
- Condition identifier
- EFO_0000220
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000272
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000632
- Condition identifier
- EFO_0000694
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000772
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002609
- Condition identifier
- EFO_0002950
- Condition identifier
- EFO_0003929
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005222
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005226
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005672
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006510
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007248
- Condition identifier
- EFO_0007328
- Condition identifier
- EFO_0007411
- Highest recorded phase
- 3
- Condition identifier
- EFO_0022597
- Condition identifier
- EFO_1000158
- Highest recorded phase
- 1
- Condition identifier
- EFO_1000453
- Condition identifier
- EFO_1001318
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001413
- Highest recorded phase
- 3
- Condition identifier
- HP_0001871
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004948
- Highest recorded phase
- 2
And 19 more, listed on the interactive page.
- Event
- anal fistula
- Reports
- 5
- Reporting signal score
- 12.11
- Event
- anti-neutrophil cytoplasmic antibody positive vasculitis
- Reports
- 4
- Reporting signal score
- 11.0767
- Event
- areflexia
- Reports
- 4
- Reporting signal score
- 10.2423
- Event
- asthma
- Reports
- 37
- Reporting signal score
- 66.0193
- Event
- benign prostatic hyperplasia
- Reports
- 9
- Reporting signal score
- 27.4353
- Event
- blood pressure increased
- Reports
- 19
- Reporting signal score
- 16.3259
- Event
- blood pressure systolic increased
- Reports
- 10
- Reporting signal score
- 18.7541
- Event
- breath sounds abnormal
- Reports
- 10
- Reporting signal score
- 31.9322
- Event
- bronchiectasis
- Reports
- 15
- Reporting signal score
- 48.0277
- Event
- bronchitis
- Reports
- 13
- Reporting signal score
- 11.7964
- Event
- bronchopulmonary aspergillosis allergic
- Reports
- 5
- Reporting signal score
- 22.0057
- Event
- burns second degree
- Reports
- 5
- Reporting signal score
- 18.9534
- Event
- chills
- Reports
- 19
- Reporting signal score
- 16.2569
- Event
- chronic obstructive pulmonary disease
- Reports
- 63
- Reporting signal score
- 185.916
- Event
- congenital hiatus hernia
- Reports
- 9
- Reporting signal score
- 69.9765
- Event
- congenital pulmonary hypertension
- Reports
- 5
- Reporting signal score
- 27.0969
- Event
- congenital tricuspid valve incompetence
- Reports
- 6
- Reporting signal score
- 32.8042
- Event
- coordination abnormal
- Reports
- 9
- Reporting signal score
- 19.1236
- Event
- cough
- Reports
- 29
- Reporting signal score
- 18.048
- Event
- diabetic neuropathy
- Reports
- 9
- Reporting signal score
- 29.9571
- Event
- drug hypersensitivity
- Reports
- 67
- Reporting signal score
- 78.8563
- Event
- drug interaction
- Reports
- 55
- Reporting signal score
- 65.3288
- Event
- dyspnoea
- Reports
- 59
- Reporting signal score
- 33.8613
- Event
- dyspnoea exertional
- Reports
- 10
- Reporting signal score
- 12.1625
- Event
- electrocardiogram qt prolonged
- Reports
- 15
- Reporting signal score
- 18.8629
And 64 more, listed on the interactive page.
- NCT00001127
- NCT00006146
- NCT00111579
- NCT00115531
- NCT00136331
- NCT00161811
- NCT00161837
- NCT00170443
- NCT00170547
- NCT00192179
- NCT00192309
- NCT00192322
- NCT00192413
- NCT00197223
- NCT00216242
- NCT00231907
- NCT00231920
- NCT00232947
- NCT00242424
- NCT00258934
- NCT00264576
- NCT00289510
- NCT00306527
- NCT00307177
- NCT00310648
And 243 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (147)
- 2013/2017 H7N9 Prime-Boost Interval
- A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months
- A Phase 2 Study to Evaluate Immune Responses of FluMist®
- A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
- A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine
- A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine
- A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine
- A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants
- A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk
- A Study of Influenza Virus Vaccines in Children and Adults
- A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine
- A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population
- A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine
- A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population
- A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer
- A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
- A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years
- A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
- A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children
- A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
In development for (30)
- Acute coronary syndrome Phase 3
- Acute lymphoblastic leukemia Phase 1
- Asthma Phase 3
- Astrocytoma (excluding glioblastoma) Phase 2
- Avian influenza Phase 3
- B-cell chronic lymphocytic leukemia Phase 2
- Breast cancer Phase 1
- Cancer Phase 1
- Central nervous system neoplasm Phase 1
- Colorectal cancer Phase 2
- COVID-19 Phase 3
- Escherichia coli infection Phase 3
- Exocrine pancreatic carcinoma Phase 2
- Gonorrhea Phase 2
- Head and neck cancer Phase 1
- Head and neck squamous cell carcinoma Phase 1
- Hematologic disorder Phase 2
- Herpes zoster Phase 3
- HIV infectious disease Phase 2
- Influenza Phase 3